The toxicity of deglycosylated ricin a chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: A retrospective analysis of patients in five clinical trials

J. Schindler, E. Sausville, R. Messmann, J. W. Uhr, E. S. Vitetta

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

A retrospective analysis of 102 patients with relapsed, non-Hodgkin's lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five Phase I clinical trials indicates that the dose-limiting toxicity, vascular leak syndrome, was more frequent and more severe in patients who had undergone prior radiotherapy (RT). Excluding patients with prior RT from the calculations of the maximum tolerated dose indicates that the maximum tolerated doses of these ITs had not been reached in any trial and are clearly higher than reported previously. Excluding patients with prior RT from future clinical trials may increase the dose of ITs that can be given in the absence of severe vascular leak syndrome.

Original languageEnglish (US)
Pages (from-to)255-258
Number of pages4
JournalClinical Cancer Research
Volume7
Issue number2
StatePublished - 2001

Fingerprint

Ricin
Immunotoxins
Non-Hodgkin's Lymphoma
Radiotherapy
Clinical Trials
Maximum Tolerated Dose
Blood Vessels
Clinical Trials, Phase I

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{aa104e6598a748f7a16e42c4fe1737be,
title = "The toxicity of deglycosylated ricin a chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: A retrospective analysis of patients in five clinical trials",
abstract = "A retrospective analysis of 102 patients with relapsed, non-Hodgkin's lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five Phase I clinical trials indicates that the dose-limiting toxicity, vascular leak syndrome, was more frequent and more severe in patients who had undergone prior radiotherapy (RT). Excluding patients with prior RT from the calculations of the maximum tolerated dose indicates that the maximum tolerated doses of these ITs had not been reached in any trial and are clearly higher than reported previously. Excluding patients with prior RT from future clinical trials may increase the dose of ITs that can be given in the absence of severe vascular leak syndrome.",
author = "J. Schindler and E. Sausville and R. Messmann and Uhr, {J. W.} and Vitetta, {E. S.}",
year = "2001",
language = "English (US)",
volume = "7",
pages = "255--258",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - The toxicity of deglycosylated ricin a chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy

T2 - A retrospective analysis of patients in five clinical trials

AU - Schindler, J.

AU - Sausville, E.

AU - Messmann, R.

AU - Uhr, J. W.

AU - Vitetta, E. S.

PY - 2001

Y1 - 2001

N2 - A retrospective analysis of 102 patients with relapsed, non-Hodgkin's lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five Phase I clinical trials indicates that the dose-limiting toxicity, vascular leak syndrome, was more frequent and more severe in patients who had undergone prior radiotherapy (RT). Excluding patients with prior RT from the calculations of the maximum tolerated dose indicates that the maximum tolerated doses of these ITs had not been reached in any trial and are clearly higher than reported previously. Excluding patients with prior RT from future clinical trials may increase the dose of ITs that can be given in the absence of severe vascular leak syndrome.

AB - A retrospective analysis of 102 patients with relapsed, non-Hodgkin's lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five Phase I clinical trials indicates that the dose-limiting toxicity, vascular leak syndrome, was more frequent and more severe in patients who had undergone prior radiotherapy (RT). Excluding patients with prior RT from the calculations of the maximum tolerated dose indicates that the maximum tolerated doses of these ITs had not been reached in any trial and are clearly higher than reported previously. Excluding patients with prior RT from future clinical trials may increase the dose of ITs that can be given in the absence of severe vascular leak syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0035126881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035126881&partnerID=8YFLogxK

M3 - Article

C2 - 11234876

AN - SCOPUS:0035126881

VL - 7

SP - 255

EP - 258

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -